Covid-19 roundup: Cancer biotech to submit EUA for Covid drug; FDA OKs Eli Lilly JAK inhibitor
As vaccine talk wanes, re-purposed treatments take center stage for Covid-19.
Veru, which started out as a cancer outfit, plans to request an EUA for its drug sabizabulin as a Covid-19 treatment for patients at high risk for acute respiratory distress syndrome (ARDS), it announced today.
Last month, Veru said its Phase III study for its Covid-19 treatment was shut down by an independent data monitoring committee due to the drug’s “overwhelming efficacy.” According to the company, sabizabulin reduced deaths by 55% compared to the standard of care group, which received remdesivir, dexamethasone, antibodies, and JAK inhibitors.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.